0.73
Precedente Chiudi:
$0.7249
Aprire:
$0.7211
Volume 24 ore:
423.42K
Relative Volume:
2.22
Capitalizzazione di mercato:
$91.46M
Reddito:
-
Utile/perdita netta:
$-70.78M
Rapporto P/E:
-1.3036
EPS:
-0.56
Flusso di cassa netto:
$-61.27M
1 W Prestazione:
+1.67%
1M Prestazione:
-2.28%
6M Prestazione:
-56.55%
1 anno Prestazione:
-67.84%
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Nome
Nautilus Biotechnology Inc
Settore
Industria
Telefono
206-333-2001
Indirizzo
2701 EASTLAKE AVE EAST, SEATTLE
Confronta NAUT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
NAUT
Nautilus Biotechnology Inc
|
0.73 | 91.46M | 0 | -70.78M | -61.27M | -0.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-05 | Downgrade | Goldman | Neutral → Sell |
2024-06-27 | Iniziato | Guggenheim | Buy |
2024-06-03 | Ripresa | Jefferies | Hold |
2022-01-06 | Iniziato | Morgan Stanley | Equal-Weight |
2021-11-02 | Iniziato | Cowen | Outperform |
2021-08-04 | Iniziato | Goldman | Neutral |
2021-07-13 | Iniziato | Jefferies | Buy |
Mostra tutto
Nautilus Biotechnology Inc Borsa (NAUT) Ultime notizie
Millennium Management LLC Purchases Shares of 37,704 Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Millennium Management LLC Has $171,000 Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
26,324 Shares in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Purchased by Squarepoint Ops LLC - Defense World
Home Product Center Public (OTCMKTS:HPCRF) Trading Up 20.5% – Should You Buy? - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Bought by Jane Street Group LLC - Defense World
Citadel Advisors LLC Raises Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Tenpoint Therapeutics Ltd. Appoints Melissa Epperly as Chief Financial Officer - Business Wire
Northern Trust Corp Sells 32,695 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
20,256 Shares in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Purchased by Cubist Systematic Strategies LLC - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Nautilus Biotechnology And 2 Other Penny Stocks With Promising Potential - Yahoo Finance
Insiders continue to buy Nautilus Biotechnology, Inc. (NASDAQ:NAUT) and now own 31% shares - simplywall.st
Nautilus Biotechnology chief scientist buys $9,885 in common stock By Investing.com - Investing.com Nigeria
Hsbc Holdings PLC Has $92,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Barclays PLC Buys 19,030 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology chief scientist buys $9,885 in common stock - Investing.com
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award - Barchart.com
Renaissance Technologies LLC Acquires 95,521 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
JPMorgan Chase & Co. Raises Stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Update - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2025 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology Reports Q1 2025 Financial Results - TipRanks
Nautilus Biotechnology targets late 2026 platform launch amid proteoform assay advancements - MSN
Nautilus Biotech’s Earnings Call Highlights Progress and Promise - TipRanks
Nautilus Biotechnology Reports First Quarter 2025 Financial Results - GlobeNewswire
Earnings call transcript: Nautilus Biotechnology Q1 2025 surprises with EPS beat - Investing.com
Nautilus Biotechnology (NAUT) Anticipates Tau Proteoform Assay L - GuruFocus
Nautilus Biotechnology Posts Qtrly Loss Per Share $0.13 - marketscreener.com
Nautilus Biotechnology (NAUT) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News
Nautilus Biotechnology (NAUT) to Release Earnings on Tuesday - Defense World
Nautilus Biotechnology Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Increases By 20.5% - Defense World
Wells Fargo & Company MN Sells 12,607 Shares of Commercial Metals (NYSE:CMC) - Defense World
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025 - The Manila Times
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer - MarketScreener
NAUT Stock Plummets to 52-Week Low at $0.82 Amid Market Turbulence By Investing.com - Investing.com South Africa
NAUT Stock Plummets to 52-Week Low at $0.82 Amid Market Turbulence - Investing.com India
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Position Decreased by Charles Schwab Investment Management Inc. - Defense World
Virtu Financial LLC Takes $28,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
We're Keeping An Eye On Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate - Yahoo Finance
Nautilus Biotechnology: Hold Rating Amid Delayed Launch and Strategic Adjustments - TipRanks
Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges - TipRanks
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology lays off 16% of workforce, plans release of commercial platform in 2026 - MSN
Nautilus: Trading Below An Albeit Lower Net Cash Figure (NASDAQ:NAUT) - Seeking Alpha
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating - Investing.com
Nautilus Biotechnology Inc Azioni (NAUT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nautilus Biotechnology Inc Azioni (NAUT) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Mallick Parag | Chief Scientist |
May 08 '25 |
Buy |
0.73 |
12,000 |
8,788 |
20,491,892 |
Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):